Evidence map›Paper›PMID 41732384›Full record

ReviewMaterials today. Bio2026

T cell-inspired therapeutic delivery platforms: From nanomedicines to cell therapy.

Nasrullah Jan, Hassan Shah, Safiullah Khan, Naveed Ullah Khan, Yan Li, Xinwei Zhang, Guixiu Shi

Abstract readReview
In one paragraph

Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nasrullah JanDepartment of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, PR China.
Hassan ShahDepartment of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital, School of Biomedical Engineering, Guangzhou Medical University, Guangzhou, Guangdong, PR China.
Safiullah KhanDepartment of Pharmacy, Iqra University, H-9 Campus Islamabad, Islamabad, Pakistan.
Naveed Ullah KhanAffiliated Hospital Guangdong Medical University, Zhanjiang, PR China.
Yan LiDepartment of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, PR China.
Xinwei ZhangDepartment of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, PR China.
Guixiu ShiDepartment of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted nanodrug delivery has garnered significant interest as a carrier for drugs, genes, and vaccines. Despite their clinical potential, these nanocarriers face substantial challenges due to their exogenous nature. These challenges can be addressed by employing T cell-inspired approaches for targeted therapies. T cell-inspired approaches-including T cell membrane-coated nanoparticles, T cell-derived exosomes, T cell hitchhiking, and chimeric antigen receptor (CAR)-T cells-exhibit remarkable properties such as inherent biocompatibility and biodegradability, prolonged circulation lifespan, and the ability to traverse biological barriers. Utilizing T cells as delivery vehicles enables prolonged circulation time and targeted drug transport, along with reduced toxicity to cells and tissues. This review explores innovative T cell-derived approaches, including T cell membrane-coated nanoparticles, T cell-derived exosomes, T cell hitchhiking, and CAR-T cells. We discuss how these methods improve biodistribution, tissue penetration, and immune evasion while preserving T cell functionality in cancer therapies, autoimmune disorders, cardiovascular diseases, and infectious diseases. By comparing conventional nanomedicine approaches with emerging T cell-based delivery systems, this review explores the transformative capability of T cell-inspired delivery in enhancing therapeutic outcomes. Finally, we address current limitations and future directions, including advanced engineering techniques, which could further refine this promising approaches.

Indexed as

CAR T cell therapyDrug deliveryNanomedicinesT cell

Identifiers

PMID41732384
PMCPMC12925206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.